Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Orion Oyj

Market Cap 9.38B 10.89B 8.64B 8.1B 15.22B 1,029B 15.37B 102B 39.89B 504B 40.86B 40B 1,744B P/E Ratio 2026 *
17.2x
P/E Ratio 2027 * 14.9x
Enterprise Value 9.3B 10.79B 8.56B 8.03B 15.09B 1,020B 15.24B 101B 39.54B 500B 40.5B 39.65B 1,729B EV / Sales 2026 *
4.5x
EV / Sales 2027 * 3.93x
Free-Float
90.5%
Yield 2026 *
2.84%
Yield 2027 * 3.08%
1 day+4.81%
3 months+4.81%
6 months+1.78%
Current year+1.78%
Current year 78.95
Extreme 78.95
82.75
1 year 78.95
Extreme 78.95
82.75
3 years 37
Extreme 37
82.75
5 years 37
Extreme 37
82.75
10 years 27.35
Extreme 27.35
82.75
Manager TitleAgeSince
Chief Executive Officer 59 2022-10-31
Director of Finance/CFO 50 2024-04-30
Chief Operating Officer 46 2021-12-31
Director TitleAgeSince
Director/Board Member 63 2017-03-21
Director/Board Member 65 2017-03-21
Director/Board Member 66 2020-05-05
Change 5-day change 1-year change 3-year change Capi.($)
+4.81%-.--% - - 11.15B
-0.32%-1.72%+39.84%+148.79% 1,010B
-2.16%+1.51%+51.82%+43.93% 580B
-2.70%-0.66%+16.10%+63.07% 402B
-0.46%0.00%+21.28%+19.14% 330B
-1.52%+1.90%+23.73%+34.08% 281B
-1.95%-4.75%+20.15%+14.68% 280B
-0.57%+0.62%-44.67%-47.65% 197B
-1.31%+1.39%+18.60%+53.45% 192B
-0.38%-2.97%+12.15%+57.34% 156B
Average -0.54%+0.84%+17.67%+42.98% 380.97B
Weighted average by Cap. -1.06%+1.04%+27.06%+67.37%

Financials

2026 *2027 *
Net sales 2.07B 2.4B 1.9B 1.78B 3.35B 227B 3.38B 22.48B 8.78B 111B 9B 8.81B 384B 2.31B 2.68B 2.12B 1.99B 3.74B 253B 3.78B 25.11B 9.81B 124B 10.05B 9.84B 429B
Net income 543M 630M 500M 469M 881M 59.56B 890M 5.91B 2.31B 29.17B 2.36B 2.31B 101B 628M 728M 578M 542M 1.02B 68.85B 1.03B 6.83B 2.67B 33.72B 2.73B 2.68B 117B
Net Debt -82.12M -95.28M -75.58M -70.9M -133M -9B -135M -893M -349M -4.41B -358M -350M -15.26B -308M -357M -283M -266M -499M -33.74B -504M -3.35B -1.31B -16.52B -1.34B -1.31B -57.18B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,132
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
66.60EUR
Average target price
74.17EUR
Spread / Average Target
+11.36%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!